Sarepta Therapeutics, Inc.
NEWS
About two years ago, former president and chief executive officer of Sarepta Therapeutics, Chris Garabedian, formed Xontogeny, a biotech accelerator. Xontogeny was founded to support life science technology startups.
Pfizer Inc. has dosed its first patient in a Phase Ib clinical trial of PF-06939926 for Duchenne muscular dystrophy (DMD). At the moment, the only approved drug is Sarepta Therapeutics’ Exondys 51 (eteplirsen).
Sarepta Therapeutics is breathing a little easier this morning. On Wednesday a federal appeals court supported a previous court’s decision to dismiss charges that the company misled shareholders as it vied to gain approval for its Duchenne muscular dystrophy treatment.
A U.S. Food and Drug Administration announced their decision to slap a clinical hold on Solid Biosciences Inc.’s experimental gene therapy treatment for Duchenne muscular dystrophy.
After a hard-fought battle to win the green light for Exondys 51 from the U.S. Food and Drug Administration, Sarepta Therapeutics is planning on seeking approval of a second treatment for Duchenne muscular dystrophy (DMD).
But the biotech swiftly indicated that it doesn’t expect the halt to last for long.
A new RBC report is reasonably positive on the biotech sector for 2018 and here are some reasons why.
In an overall good year for pharma and biotech sectors, there have been some standouts.
Rick Duprey, writing for The Motley Fool, takes a look at three biotech stocks that have quadrupled this year.
JOBS
IN THE PRESS